Introduction
============

Among Korean patients aged 18 years and over, 14.6% have arthritis.[@b1-ppa-10-641] Arthritis affects patients' quality of life by causing pain and impairing physical joint function. Korean patients generally take selective cyclooxygenase-2 (Cox-2) inhibitors in nonsteroidal anti-inflammatory drugs (NSAIDs) as a palliative therapy to reduce arthritis symptoms. While the beneficial effects of NSAIDs, such as pain reduction and functional improvement, are well established, they cause progressive gastrointestinal (GI) adverse events including nausea, vomiting, dyspepsia, and abdominal pain.[@b2-ppa-10-641]--[@b5-ppa-10-641] Cox-2 inhibitors increase the risk of thrombotic cardiovascular (CV) events, such as myocardial infarctions and stroke.[@b6-ppa-10-641],[@b7-ppa-10-641] Rofecoxib was representatively withdrawn because of reporting adverse event after approval.[@b8-ppa-10-641]

Typically, regulatory agencies approve medicines that have benefits that outweigh their risks; however, the benefit--risk balance can be altered after approval owing to additional information regarding efficacy and adverse events. In this respect, major regulatory agencies, such as the European Medicines Agency and the Food and Drug Administration (FDA), and research institutes, such as the Innovative Medicines Initiative, are interested in developing quantitative methods for evaluating the benefit--risk balance and integrating benefit--risk trade-offs in all decision making, even that of patients.[@b9-ppa-10-641]--[@b11-ppa-10-641] In addition, the importance of patients' preference has been increasingly emphasized in recent years, and, this is the reason why differences between two groups can limit the efficacy of drug treatments.[@b12-ppa-10-641],[@b13-ppa-10-641] To increase the likelihood of successful treatment outcomes, physicians should understand and respect patient preferences. Nevertheless, there was little evidence of comparison with the preference between two groups.

This study was aimed at quantifying the benefit--risk preferences of Korean patients and physicians using discrete choice experiments (DCEs), the results of which were used to assess the relative importance of benefits and maximum acceptable risk (MAR) during the decision to treat arthritis with Cox-2 inhibitors.

Materials and methods
=====================

DCE development
---------------

DCEs have been utilized to quantitatively identify benefit--risk preference-weights for Cox-2 inhibitors.[@b14-ppa-10-641]--[@b18-ppa-10-641] DCEs afford systematic evaluation of preferences in diverse treatments using trade-offs between attributes. Preferences are elucidated by having respondents repeatedly choose their preferred hypothetical option.

### Defining attributes and levels through systematic review

We included the best-selling celecoxib, along with etoricoxib, which sells differently by country, and rofecoxib, which has been withdrawn. This was because the objective of this study was to elicit preferences for the benefits and risks of Cox-2 inhibitors, and we intended to include the comprehensive preference level from the least preferred to most preferred by selecting three Cox-2 inhibitors.

Developing a DCE required a systematic review to define the attributes and levels for hypothetical treatment outcomes. Systematic literature reviews to collect data regarding the use of each selected Cox-2 inhibitor in osteoarthritis (OA) or rheumatoid arthritis patients were performed between January 1996 and August 2014. Data were collected from publicly available FDA drug documents,[@b19-ppa-10-641]--[@b24-ppa-10-641] and published clinical trials and observational studies[@b25-ppa-10-641]--[@b43-ppa-10-641] accessed through MEDLINE, and the Cochrane Central Register of Controlled Trials. According to predefined inclusion criteria, six FDA drug documents were selected, while 38 clinical trials from selected reports were included. Our inclusion criteria for data were defined as follows: 1) adult OA or rheumatoid arthritis patients, 2) subjects reported a change in index scores for main symptom relief while taking one of the three selected Cox-2 inhibitors over 4 weeks, 3) subjects reported serious adverse events, 4) reports from randomized clinical trials or observational studies, and 5) evidence reported in English or Korean.

During the literature review, four attributes were extracted from FDA drug documents and selected papers. Two primary beneficial end points from the literature were defined: 1) reduction rate in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score from baseline (PAI) and 2) a reduction rate in WOMAC physical function scale from baseline (FUN). The WOMAC scores are commonly utilized to evaluate the efficacy of treatment for arthritis and it allows for the comparison of the efficacy of Cox-2 inhibitor treatment for arthritis patients. The WOMAC consists of three parts allowing assessment of pain, stiffness, and joint function. In the WOMAC scores, improvement in individual subjects was defined as a decrease in the pain and physical function scores.[@b44-ppa-10-641] However, in this study, subjects did not directly undergo assessment of their WOMAC scores and the WOMAC pain and physical functional scores for three Cox-2 inhibitor drugs were extracted through a systematic review. Risk attributes were defined from serious adverse events reported frequently throughout the literature, including 1) upper GI complications and 2) CV adverse events.

To define response levels for the selected attributes in the questionnaires for two hypothetical Cox-2 inhibitors, we performed mixed treatment comparisons (MTC) for rofecoxib, celecoxib, and etoricoxib. The MTC were necessary because of inadequate direct comparisons between the treatment outcomes of the three selected Cox-2 inhibitors in the literature. The levels used in quantifying the attributes were based on the median results from the MTC; this analysis was conducted using WinBUGS 1.4.3 statistical software (MRC Biostatistics Unit, Cambridge, England) to estimate the values for each Cox-2 inhibitor attribute. The random-effects MTC model was used because there was heterogeneity among the rofecoxib, celecoxib, and etoricoxib studies.[@b45-ppa-10-641] The four selected attributes, each with three evaluation levels, are shown in [Table 1](#t1-ppa-10-641){ref-type="table"}.

### Designing the questionnaires for survey using DCE approach

The hypothetical options were designed to satisfy orthogonality, minimum overlapping, and equal balance.[@b46-ppa-10-641] The experimental design was optimized using D-efficiency from the SAS software package (version 9.3, SAS Institute Inc., Cary, NC, USA). Eighteen choice-based questionnaire sets were generated and checked for internal consistency and rationality. In each questionnaire, all respondents had to select their preferred Cox-2 treatment between two hypothetical alternatives ([Figure 1](#f1-ppa-10-641){ref-type="fig"}).

Survey subjects
---------------

One hundred Korean patients and 60 Korean physicians were recruited from a Hankook Research (Gangnam, Seoul, South Korea) panel. Patients were selected according to the following criteria: 1) have a diagnosis of OA or rheumatoid arthritis in panel clinics, 2) set a quote similarly reflecting the sex and age of the target patients, 3) take oral Cox-2 inhibitors or other NSAIDs, and 4) subjects sign the participation consent form in the surveys. Interviewers confirmed whether patients had a diagnosis from their doctors. Physicians in the panel were required to be board-certified orthopedic surgeons in South Korea ([Figure 2](#f2-ppa-10-641){ref-type="fig"}). All respondents were interviewed by an educated interviewee to reduce bias. The study and survey questionnaires used, were approved by the Sungkyunkwan University Institutional Review Board (Approval No SKKU-2014-07-002-002).

Data analysis
-------------

We compared patients' and physicians' preferences for the benefits and risks of Cox-2 inhibitors across various aspects, including preference weight, perception, relative importance, and MAR.

The preference data for patients and physicians were estimated by conditional logistic regression using SAS 9.3 software; respondents who did not select the dominant option were excluded. Data were categorized by an effects-coded model based on previously published guidelines.[@b47-ppa-10-641] The coefficients in this model were estimated for each group; these coefficients represented the preference for each level within each attribute of each group. A positive coefficient for an attribute level indicates a preference for that level over other levels within that attribute. Conversely, a negative coefficient for an attribute level indicates a reduced preference for that level over other levels within that attribute. Accordingly, a higher coefficient means a more preferred level in each attribute. A statistically significant coefficient indicates that the attribute level influences the respondents' treatment decisions.

The equation of the conditional logit model was as follows: $$\begin{array}{l}
{U(\text{binery~choice})} \\
{\mspace{9mu} = PAT \times (\beta_{\text{PAI}1} \times \text{PAI}_{1} + \beta_{\text{PAI}2} \times \text{PAI}_{2} + \beta_{\text{PAI}3} \times \text{PAI}_{3}} \\
{\mspace{14mu} + \beta_{\text{FUN}1} \times \text{FUN}_{1} + \beta_{\text{FUN}2} + \text{FUN}_{2} + \beta_{\text{FUN}3} \times \text{FUN}_{3}} \\
{\mspace{14mu} + \beta_{\text{GI}1} \times \text{GI}_{1} + \beta_{\text{GI}2} \times \text{GI}_{2} + \beta_{\text{GI}3} \times \text{GI}_{3} + \beta_{\text{CV}1} \times \text{CV}_{1}} \\
{\mspace{14mu} + \beta_{\text{CV}2} \times \text{CV}_{2} + \beta_{\text{CV}3} \times \text{CV}_{3}) + PHY \times (\beta_{\text{PAI}1} \times \text{PAI}_{1}} \\
{\mspace{14mu} + \beta_{\text{PAI}2} \times \text{PAI}_{2} + \beta_{\text{PAI}3} \times \text{PAI}_{3} + \beta_{\text{FUN}1} \times \text{FUN}_{1}} \\
{\mspace{14mu} + \beta_{\text{FUN}2} \times \text{FUN}_{2} + \beta_{\text{FUN}3} \times \text{FUN}_{3} + \beta_{\text{GI}1} \times \text{GI}_{1}} \\
{\mspace{14mu} + \beta_{\text{GI}2} \times \text{GI}_{2} + \beta_{\text{GI}3} \times \text{GI}_{3} + \beta_{\text{CV}1} \times \text{CV}_{1} + \beta_{\text{CV}2} \times \text{CV}_{2}} \\
{\mspace{14mu} + \beta_{\text{CV}3} \times \text{CV}_{3})} \\
\end{array}$$where *U* is the binary choice for the hypothetical Cox-2 inhibitor pair and *PAT* and *PHY* are dummy variables. *PAT* was 1 and *PHY* was 0 when the subjects were patients. Other variables are shown in [Table 1](#t1-ppa-10-641){ref-type="table"}. The Z-test was conducted to compare the coefficient between patients and physicians. This approach is utilized to compare the coefficient in regression which was estimated via maximum likelihood such as a conditional logit model.[@b48-ppa-10-641]

Preference weight, indicating the relative degree of preference for that specific level or attribute, was calculated using the coefficient difference between one level and the other level within a specific attribute. It was interpreted as the subjects' perception of the change in benefit--risk attribute level.[@b49-ppa-10-641] We compared each groups' perceptions of changes in benefit and risk outcomes. If the respondents perceived an equal value for changing levels within a specific attribute, then the preference weight was equal. For example, the respondent had equal perception if the preference weight for improving from the moderate level to the best level within the PAI attribute was equal to 1 and the preference weight for declining from the moderate level to the worst level within the CV attribute was 1.

Furthermore, we estimated relative importance as a subset of the preference weights. The relative importance is the relative preference weight for each attribute over all attributes. The greater the relative importance between the four attributes, the more significant the attribute was for decision making.

Lastly, MAR was estimated using the coefficient ratio from the regression. MAR is interpreted as the highest level of treatment-related risk that respondents were willing to accept.[@b15-ppa-10-641] MAR indicated the trade-off between beneficial attributes (PAI and FUN) and risk attributes (GI and CV). We used Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) and 1,000 bootstrap values to determine the MAR with 95% confidence intervals (CIs).

Results
=======

Of the 160 interviewees, two were excluded owing to inconsistent or incomplete responses. The remaining 158 respondents consisted of 98 patients and 60 physicians. From this DCE approach, 98.8% of respondents rationally preferred the dominant Cox-2 inhibitor when informed regarding the trade-offs between the benefit--risk attributes, meaning that patients and physicians gave their attention to the questionnaire. [Table 2](#t2-ppa-10-641){ref-type="table"} summarizes descriptive statistics for the 158 respondents included in the study. The patient respondents had a mean (standard deviation \[SD\]) age of 55.7 (7.8) years and 69% were female. In addition, the most commonly diagnosed disease was OA, at 63%, and the most commonly experienced adverse events were GI, at 40%. Forty-five percent of the physicians had more than 10 years of clinical experience and 98% were male.

Preference weights for benefit--risk of Cox-2 inhibitors using DCE
------------------------------------------------------------------

The major results of the conditional logit model are shown in [Table 3](#t3-ppa-10-641){ref-type="table"}. As expected, patients and physicians preferred Cox-2 inhibitors with improved PAI or FUN outcomes and those with reduced occurrences of GI or CV adverse events, as identified by higher coefficients for improved PAI or FUN and by lower coefficients for more severe adverse events. However, differences in the preference for each level within certain attributes between patients and physicians were statistically significant, as confirmed by the Z-test. The preferred outcome rankings for patients and physicians associated with the benefit--risks of Cox-2 inhibitors were also different. For example, patients valued the 55% reduction in WOMAC scores for pain as the most preferential outcome (coefficient: 1.1 \[standard error; SE: 0.10\], *P*-value: \<0.0001). Conversely, physicians ranked the lowest CV adverse event occurrence (0.4%) as the most preferred outcome (coefficient: 1.1 \[SE: 0.10\], *P*-value: \<0.0001). In subgroup analysis, we did not find a statistically significant difference between patients with rheumatoid arthritis and OA.

We also identified the manner in which patients' and physicians' perceptions changed with benefit levels and risk levels using preference weights. Patients displayed preference weights lower than those of physicians for reducing GI adverse events from 5% to 3% ([Figure 3](#f3-ppa-10-641){ref-type="fig"}). Patients displayed a preference weight for improving pain reduction from 55% to 45% (Δ0.7 units) and a preference weight for reducing the occurrence of GI adverse events from 5% to 3% (Δ0.8 units). Physicians displayed a preference weight for reducing GI adverse events from 5% to 3% (Δ1.1 units) and increasing joint function improvement from 15% to 35% (Δ1.2 units).

In addition, we compared the relative importance ranking of risks and benefits among patient and physician groups ([Figure 4](#f4-ppa-10-641){ref-type="fig"}). In the present study, Korean patients placed a high value on beneficial attributes, whereas physicians evaluated CV adverse events as the most important attribute. Among the patients, the relative importance of the benefit attributes, PAI (35.2%) and FUN (30.0%), outweighed that of the risk attributes, CV adverse events (21.4%) and GI adverse events (13.4%), while the CV adverse event risk outweighed the benefit attributes among physicians. Physicians considered CV adverse events (33.5%) as the most important attribute, followed by PAI (32.4%), GI adverse events (18.1%), and FUN (16.0%).

Risk tolerance (MAR)
--------------------

We compared the extent to which patients and physicians were willing to trade the level of risks associated with Cox-2 inhibitors for improving PAI or FUN ([Table 4](#t4-ppa-10-641){ref-type="table"}).

There was a difference in the willingness of patients and physicians to accept the maximum risk for each benefit attribute. Patients were more willing than physicians to accept risk upon improvement of pain reduction from 20% or 45% to 55% (the best treatment response level). For example, patients were, respectively, willing to accept a 1.5% risk for GI adverse events (95% CI: 1.46--1.48) and a 1.4% risk for CV adverse events (1.42--1.44) to improve pain reduction from 45% to 55%, while physicians were willing to accept a 0.6% risk for GI adverse events (0.57--0.59) and a 0.6% risk for CV adverse events (0.61--0.63) to improve pain reduction from 45% to 55%. A similar trend was found in the trade-off between risk and improving physical joint function.

However, interestingly, patients and physicians had some trends in common with regard to MARs. First, both groups were willing to accept the maximum GI and CV risk when the pain reduction was increased from a 20% reduction to a 55% reduction. Second, both groups were similarly willing to accept the maximum risk for improving both benefit attributes regardless of the risk type (GI or CV adverse event).

Discussion
==========

In this paper, using a DCE approach, we directly compared the benefit--risk trade-offs as reported by Korean patients and physicians regarding Cox-2 inhibitors as treatments for arthritis, leading to several meaningful results. Our results demonstrated the preference gap between patients and physicians regarding Cox-2 inhibitors. We found that patients were more concerned with the benefits of Cox-2 inhibitors, such as PAI and FUN, than with the risk of GI and CV adverse events, whereas physicians considered CV adverse events to be the most important attribute among the four tested attributes. In addition, we found patients were more willing than physicians to accept risk upon improvement of both beneficial attributes from their worst levels or moderate levels to their best treatment response levels. With respect to decreased PAI, patients were more willing by 1.6 (=2.1/1.3) times to face a GI risk and by 1.5 (=2.1/1.4) times to face a CV risk than physicians. Notably, with respect to improved FUN, patients were more willing by 3.3 (=2.0/0.6) times to face a GI risk and by 3.2 (=1.9/0.6) times to face a CV risk than physicians, whereas each group ranked the two beneficial attributes (PAI and FUN) and two risk attributes (GI and CV) similarly. With regard to the two benefit attributes, patients and physicians ranked PAI as more important than FUN. With regard to the two risk attributes, CV was more important than GI for physicians and patients. These results indicate that lower frequency, more severe risks, such as CV, are considered more important than more frequent, moderate risks when both patients and physicians choose treatment.

Some papers have previously examined benefit--risk preference for NSAIDs including Cox-2 inhibitors.[@b15-ppa-10-641],[@b16-ppa-10-641],[@b50-ppa-10-641],[@b51-ppa-10-641] In these studies, the preference results varied. With respect to examining the preference of physicians, one study showed that risk attributes, such as heart attack risk and stroke risk, outweighed beneficial attributes, such as ambulatory pain and resting pain.[@b15-ppa-10-641] In the present study, Korean physicians displayed preferences similar to those found in previous studies of physicians' preferences. On the other hand, with respect to elucidating the preference of patients, one study demonstrated that patients reported GI risks to be the most important attribute,[@b50-ppa-10-641] while other studies reported that patients evaluated improvement in physical mobility as the most important benefit attribute,[@b51-ppa-10-641] but Korean patients evaluated PAI to be the most important attribute.

Strengths and limitations
=========================

This comparison study of patients and physicians has a few strengths. This is the first study that quantitatively evaluates the preference for Cox-2 inhibitors and directly compares the preferences between patients and physicians using the DCE method. Furthermore, we defined the essential attributes based on a comprehensive literature review including approval documents opened by the FDA, observational studies, and various clinical trials. Finally, we confirmed that our results were robust while we demonstrated that the measured preferences were statistically significantly different for each level within a given attribute.

However, this study has several limitations. Preferences will manifest differently in the real-world because DCE measures the stated preference, not decision makers' actual choice.[@b52-ppa-10-641],[@b53-ppa-10-641] Therefore, we need to pay attention to the preference gap between our results and those of the clinical setting. Subsequently, we missed the unobserved systematic interaction and heterogeneous preferences by applying a conditional logit model. This is because the conditional logit model assumes the utility of all subjects is equal.[@b54-ppa-10-641],[@b55-ppa-10-641] In spite of this limitation, the conditional logit model is commonly utilized because it efficiently and easily estimates utility. Finally, our study included only orthopedic surgeons among the physicians. Even though a previous study showed no significant differences in the preferences between general physicians and specialists in areas including orthopedics and rheumatology when determining which NSAIDs to prescribe for patients with OA,[@b15-ppa-10-641] we should consider the possibility of a preference gap among general physicians, rheumatology specialists, and orthopedic surgeons in the clinical setting.

Conclusion
==========

Our study suggests that physicians should more fully consider the benefits to patients' quality of life and should understand that differences in perception between patients and physicians may cause miscommunication when decisions are made regarding patient treatment, in agreement with a previous study. Therefore, to reduce the preference gap between patients and physicians, we suggest that patients should be educated regarding the risks related to treatment with Cox-2 inhibitors; additionally, physicians should set a high value on the benefits to patients' quality of life. Such efforts to reduce the preference gap will help patients with arthritis and physicians successfully reach treatment goals using Cox-2 inhibitors.
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![Preference weights for benefit--risk attributes for patient and physician groups.\
**Notes:** The differences between adjacent weights indicate the relative importance of moving from one level of an attribute to an adjacent level of that attributes.\
**Abbreviations:** CV, cardiovascular; FUN, reduction rate in WOMAC physical function scale from baseline; GI, gastrointestinal; PAI, reduction rate in the WOMAC pain scale from baseline; WOMAC, Western Ontario and McMaster Universities Arthritis Index.](ppa-10-641Fig3){#f3-ppa-10-641}
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**Abbreviations:** CV, cardiovascular; FUN, reduction rate in WOMAC physical function scale from baseline; GI, gastrointestinal; PAI, reduction rate in the WOMAC pain scale from baseline; WOMAC, Western Ontario and McMaster Universities Arthritis Index.](ppa-10-641Fig4){#f4-ppa-10-641}

###### 

Treatment attributes and levels of cyclooxygenase-2 inhibitors

  Attributes                          Definition                                                                                      Level (%)                   Variable name   Coefficients
  ----------------------------------- ----------------------------------------------------------------------------------------------- --------------------------- --------------- --------------
  Benefits                                                                                                                                                                        
   Reduction in pain                  Reduction rate in the WOMAC pain scale from baseline                                            20                          PAI~1~          β~PAI1~
  45                                  PAI~2~                                                                                          β~PAI2~                                     
  55                                  PAI~3~                                                                                          β~PAI3~                                     
   Improvement of physical function   Reduction rate in WOMAC physical function scale from baseline                                   15                          FUN~1~          β~FUN1~
  35                                  FUN~2~                                                                                          β~FUN2~                                     
  45                                  FUN~3~                                                                                          β~FUN3~                                     
  Risks                                                                                                                                                                           
   Upper GI complications             Chance of upper GI complication (gastric ulcer, GI bleeding, or perforation)                    1 (1 of 100 patients)       GI~1~           β~GI1~
  3 (3 of 100 patients)               GI~2~                                                                                           β~GI2~                                      
  5 (5 of 100 patients)               GI~3~                                                                                           β~GI3~                                      
   CV adverse events                  Chance of CV adverse events (angina, myocardial infarction, congestive heart failure, stroke)   0.4 (4 of 1,000 patients)   CV~1~           β~CV1~
  1.2 (12 of 1,000 patients)          CV~2~                                                                                           β~CV2~                                      
  4 (40 of 1,000 patients)            CV~3~                                                                                           β~CV3~                                      

**Note:** ~1,2~ and ~3~ indicate the three evaluation levels.

**Abbreviations:** CV, cardiovascular; FUN, reduction rate in WOMAC physical function scale from baseline; GI, gastrointestinal; PAI, reduction rate in the WOMAC pain scale from baseline; WOMAC, Western Ontario and McMaster Universities Arthritis Index.

###### 

Respondents' baseline characteristics

  Characteristics                                                                Analysis included respondents (%)
  ------------------------------------------------------------------------------ -----------------------------------
  Patient group                                                                  98 (100)
   Age (mean ± SD)                                                               55.7±7.8
   Sex                                                                           
   Male                                                                          30 (31)
   Female                                                                        68 (69)
   Diagnosed disease                                                             
   Osteoarthritis                                                                62 (63)
   Rheumatoid arthritis                                                          29 (30)
   Both osteoarthritis and rheumatoid arthritis                                  7 (7)
   Experienced adverse event related to treatment during the treatment process   
   None                                                                          37 (38)
   Gastrointestinal disease                                                      40 (41)
   Cardiovascular disease                                                        14 (14)
   More than two diseases                                                        5 (5)
   Others                                                                        2 (2)
  Physicians (orthopedists)                                                      60 (100)
   Age (mean ± SD)                                                               40.0±4.9
   Sex                                                                           
   Male                                                                          59 (98)
   Female                                                                        1 (2)
   Underwent treatment for arthritis                                             
   \<5 years                                                                     9 (15)
   5--10 years                                                                   24 (40)
   \>10 years                                                                    27 (45)

**Note:** Data is presented as number (%) unless otherwise stated.

**Abbreviation:** SD, standard deviation.

###### 

Preferences of patient group and physician group as estimated by the regression model

  Attribute                                Patient group (n=98)     Physician group (n=60)    Comparison                                                                   
  ---------------------------------------- ------------------------ ------------------------- ------------------------ ------------------------- ------ ------- ---------- -----
  PAI                                                                                                                                                                      
   20%                                     β~PAI1~                  0.6                       0.12                     \<0.0001                  −1.5   0.16    \<0.0001   0.6
   45%                                     β~PAI2~                  0.1                       0.07                     \<0.0001                  0.5    0.09    \<0.0001   0.1
   55%                                     β~PAI3~                  0.5                       0.08                     \<0.0001                  1.0    0.129   \<0.0001   0.5
  FUN                                                                                                                                                                      
   15%                                     β~FUN1~                  0.1                       0.13                     \<0.0001                  −0.8   0.13    \<0.0001   0.1
   35%                                     β~FUN2~                  0.0                       0.07                     0.1305                    0.4    0.10    0.0001     0.0
   45%                                     β~FUN3~                  0.0                       0.10                     \<0.0001                  0.4    0.09    \<0.0001   0.0
  GI                                                                                                                                                                       
   1% (1 of 100 patients)                  β~GI1~                   0.0                       0.09                     \<0.0001                  0.5    0.10    \<0.0001   0.0
   3% (3 of 100 patients)                  β~GI2~                   0.5                       0.06                     0.0017                    0.3    0.09    0.0029     0.5
   5% (5 of 100 patients)                  β~GI3~                   0.1                       0.10                     \<0.0001                  −0.8   0.12    \<0.0001   0.1
  CV                                                                                                                                                                       
   0.4% (4 of 1,000 patients)              β~CV1~                   0.0                       0.10                     \<0.0001                  1.1    0.11    \<0.0001   0.0
   1.2% (12 of 1,000 patients)             β~CV2~                   0.6                       0.07                     0.0106                    0.2    0.08    0.004      0.6
   4.0% (40 of 1,000 patients)             β~CV3~                   0.0                       0.06                     \<0.0001                  −1.3   0.10    \<0.0001   0.0
                                                                                                                                                                           
  **Model fit statistics**                 **Without covariates**   **With covariates**       **Without covariates**   **With covariates**                                 
                                                                                                                                                                           
  AIC                                      2,037.85                 1,669.75                  1,247.67                 900.83                                              
  SC                                       2,037.85                 1,717.64                  1,247.67                 944.79                                              
  −2 Log L                                 2,037.85                 1,653.75                  1,247.67                 884.83                                              
  Testing global null hypothesis: Beta=0   Chi-square               *P*-value \> chi-square   Chi-square               *P*-value \> chi-square                             
  Likelihood ratio                         384.10                   \<0.0001                  362.84                   \<0.0001                                            
  Score                                    333.69                   \<0.0001                  314.70                   \<0.0001                                            
  Wald's equation                          230.43                   \<0.0001                  213.30                   \<0.0001                                            

**Note:** ~1,2~ and ~3~ indicate the three evaluation levels.

**Abbreviations:** AIC, Akaike information criterion; CV, cardiovascular; FUN, reduction rate in WOMAC physical function scale from baseline; GI, gastrointestinal; PAI, reduction rate in the WOMAC pain scale from baseline; SC, Schwarz criterion; SE, standard error; WOMAC, Western Ontario and McMaster Universities Arthritis Index.

###### 

MAR for patient and physician groups

  Improvement in benefit   Patient group (n=98)   Physician group (n=60)                      
  ------------------------ ---------------------- ------------------------ ------------------ ------------------
  PAI                                                                                         
   20%--45%                0.7 (0.65--0.67)       0.6 (0.63--0.65)         0.8 (0.74--0.76)   0.8 (0.79--0.81)
   45%--55%                1.5 (1.46--1.48)       1.4 (1.42--1.44)         0.6 (0.57--0.59)   0.6 (0.61--0.63)
   20%--55%                2.1 (2.11--2.15)       2.1 (2.05--2.09)         1.3 (1.32--1.34)   1.4 (1.41--1.45)
  FUN                                                                                         
   15%--35%                0.2 (0.20--0.20)       0.2 (0.20--0.20)         0.5 (0.52--0.54)   0.6 (0.56--0.58)
   35%--45%                1.8 (1.79--1.81)       1.7 (1.72--1.76)         0.1 (0.04--0.06)   0.1 (0.05--0.07)
   15%--45%                2.0 (1.99--2.01)       1.9 (1.92--1.96)         0.6 (0.57--0.59)   0.6 (0.61--0.63)

**Abbreviations:** CI, confidence interval; CV, cardiovascular; FUN, reduction rate in WOMAC physical function scale from baseline; GI, gastrointestinal; MAR, maximum acceptable risk; PAI, reduction rate in the WOMAC pain scale from baseline; WOMAC, Western Ontario and McMaster Universities Arthritis Index.
